J.-S. Lee

机构：Seoul National University Bundang Hospital

发表论文 23 篇 · 总被引 480 次 · h-index 9

代表论文

• Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer (2021 · Annals of Oncology · 被引 201)
• IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC) (2019 · Annals of Oncology · 被引 69)
• 1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose (2016 · Journal of Thoracic Oncology · 被引 38)
• OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results (2023 · Journal of Thoracic Oncology · 被引 36)
• Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19) (2019 · Annals of Oncology · 被引 34)
• First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients (2022 · ESMO Open · 被引 25)